SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TheSlowLane who wrote (46)12/14/1996 3:53:00 PM
From: James Silverman   of 675
 
Paul,
Their are quite a few firms with programs for MS. There are 3 currently marketed (or soon to be) drugs available for MS. CHIR and BGEN have beta interferon type drugs already marketed. A third, Copaxone, a Teva Ph. drug should be approved very very soon. Each of the drugs has their problems and they are not all that effective, but the category is still growing nicely.

I'm sure there are many others in clinicals, off the top of my head, AIMM has one entering Phase III, IMUL has a drug in early clinicals.
Its a very difficult disease to treat so an effective drug would be a major breakthrough. I would guess the CNSI drug is somewhere between 5 and 8 years off the market if all goes very well. So its a very LT project for them.

Still, the key for CNSI is clearly Cerestat. If its approved CNSI will do very well.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News